Medications

Combination therapy can delay resistance of lung cancer cells

A specific genetic alteration, known as an ALK fusion, drives non-small cell lung cancer in some patients. This abnormality leads to excessive activity of the ALK protein, a key cancer promoter. These tumors can be treated ...

Oncology & Cancer

Exploring ferroptosis and its implications in lung cancer

An estimated 2.2 million people suffer from lung cancer worldwide, making it the second most common type of cancer. Though improvements in treatment have been made, the overall survival rate of lung cancer patients is low, ...

page 1 from 40